[TimAlerts] $VSTM “Dr. Matthew Davids gave an oral presentation of new clinical data from the ongoing Phase Ib/II study evaluating duvelisib in combination with FCR (chemo-immunotherapy) in younger, fit CLL patients,” said Diep Le, MD, PhD, Chief Medical Officer of Verastem Oncology. “The combination regimen achieved an overall response rate (ORR) of 94%, including 26% of patients experiencing a complete response or complete response with incomplete blood count recovery (CR/CRi), and 68% achieving a partial

Received 2 Karmas

[TimAlerts] $VSTM put an alert for if it breaks back about 3.45, then I'll be interested. If it breaks 3.70, it'll break the downward LT chart pattern

Received 13 Karmas
Maoriboy Jul 12, 17 5:28 PM

Oh my gosh I cant believe that I actually understand what your saying when you explain where u went right or wrong in trades... When I first watched I thought " what the hell is he going on about.." my study is paying off!!! Thanks heaps mate ( Tim Sykes)

Cprgee Jul 12, 17 8:09 PM

Thanks Tim. Be Well

Join now or log in to leave a comment
of 26